MedTrace Logo

Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

NCT07302464 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-12-24

No results posted yet for this study

Summary

The work aimed to compare the effects of Sodium-glucose co-transporter-2 (SGLT2) inhibitors on glomerular filtration rate (GFR) in patients with diabetic chronic kidney disease (CKD) and non-diabetic CKD.

Conditions

Interventions

OTHER

Sodium Glucose Co-Transporter 2 Inhibitors

All candidates start therapy with sodium glucose co-transporter 2 (SGLT2) inhibitors with a dose of 10mg daily Dapagliflozin for 6 months

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2025-06-01
Completion
2025-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07302464 on ClinicalTrials.gov